Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Study of Dexycu in Treating Intraocular Inflammation

A legfontosabb adatok

Ki végzi
Ocumension Therapeutics (Shanghai) Co., Ltd
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
285 fő vett részt
Kezdés
2022. aug. 22.
Befejezés
2024. ápr. 9.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Dexycu
  • Placebo
A regiszteradat frissítve
2024. augusztus 26.

Ki vehet részt

Életkor
40 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • The patient must provide written informed consent by signing the Informed Consent approved by the Institutional Review Board (IRB)
  • Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation
  • The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 in the study eye and better than 20/200 in the fellow eye
  • The patient must be considered by the Investigator to have visual acuity potential. greater than 20/30 in the study eye
  • The patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology
  • A female patient of childbearing potential must have a negative pregnancy test on Day 0 and be using an effective method of birth control from Screening for the duration of the study
  • The patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel

Ki nem vehet részt

  • Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0
  • Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening
  • Patients who have received any intravitreal corticosteroid delivery vehicle (e.g.,Retisert, Ozurdex, Iluvien) in the study eye at any time
  • Patients who anticipate requiring treatment with any corticosteroids( by any route,except inhalation), during the study
  • Patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye)
  • Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to Day 0
  • Patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening
  • Patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening
  • Patients with planned intraocular or laser surgery in the study eye for the duration of the study
  • Patients who have received any prior intravitreal injections in the study eye
  • Patients with ocular hypertension with an IOP in the study eye > 21 mm Hg at Screening with or without treatment with anti-glaucoma monotherapy
  • Patients with ocular hypertension receiving treatment with two or more anti-glaucoma Medications
  • Patients treated with any investigational product within 30 days prior to screening or patients enrolled previouslyc study
  • Patients with an allergy or hypersensitivity to dexamethasone
  • Patients with a history of chronic uveitis from any cause in either eye
  • Patients with any signs of intraocular inflammation in either eye at screening
  • Patients with evidence of corneal abnormality or dystrophy (e.g. opacities, guttae,clouding, etc.) or an inability to obtain an acceptable specular micrograph at Screening
  • Patients with glaucomatous optic neuropathy or glaucomatous visual field loss in either eye

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of inflammation associated with cataract surgery.

A vizsgálat 2 csoportja

  • Dexamethasone intraocular injectionA vizsgált kezelés

    Dexamethasone implant single injection in the treatment eye after cataract surgery.

    Kezelés: Dexycu

  • PlaceboPlacebo, összehasonlításként

    Blank placebo single injection in the treatment eye after cataract surgery.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3,Prospective, Randomized, Double-masked, Placebo-controlled, Parallel Study to Evaluate the Efficacy, PK and Safety of 9% Dexamethasone Intraocular Injection for the Treatment of Inflammation Associatedwith Cataract Surgery
A regiszteradat frissítve
2024. augusztus 26.